pargyline has been researched along with Hypertrophy in 1 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianchi, P | 1 |
| Pimentel, DR | 1 |
| Murphy, MP | 1 |
| Colucci, WS | 1 |
| Parini, A | 1 |
1 other study available for pargyline and Hypertrophy
| Article | Year |
|---|---|
A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation.
Topics: Adrenergic Uptake Inhibitors; Animals; Catalase; Cells, Cultured; Enzyme Activation; Flavonoids; Gen | 2005 |